Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will develop a (a) rehabilitation strategy and (b) single accountable lead in every NHS Trust and Integrated Care Board area.
Answered by Helen Whately - Minister of State (Department of Health and Social Care)
National Health Service bodies and local authorities should ensure local recovery, rehabilitation, and reablement services are commissioned effectively and sustainably, and meet the needs of their local population. This may be provided as part of intermediate care services, and should be done in collaboration with relevant organisations, including the voluntary and community sector, and care providers.
NHS England has published the Intermediate care framework for rehabilitation, reablement and recovery following hospital discharge, which recommends systems identify an Allied Health Professional lead to progress implementation of the new model, both within the hospital and in the community.
Integrated care boards have flexibility over the arrangements of their own governance, including board membership, and are able to go beyond the statutory minimums to appoint more local authority, NHS provider, or primary care representatives to board membership, in order to tackle local priority issues.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure that intensive therapy unit patients have access to rehabilitative therapies on their discharge from hospital.
Answered by Helen Whately - Minister of State (Department of Health and Social Care)
Rehabilitation, and therapy-led reablement, are critical in ensuring that patients discharged on intermediate care pathways from acute settings receive appropriate support to recover.
As set out in the hospital discharge and community support guidance, local authorities and integrated care boards should ensure that, where appropriate, they commission rehabilitation, including therapy-led reablement, for those who need it.
Every acute hospital now has access to a care transfer hub. These hubs bring together professionals from the National Health Service and social care to ensure that patients with more complex needs have in place the most appropriate support package for their safe discharge.
Asked by: Helen Grant (Conservative - Maidstone and The Weald)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent progress she has made on retaining more GPs.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
There were 2,799 more full time equivalent (FTE) doctors working in general practice (GP) in December 2023, compared to December 2019. The Government is working with NHS England to increase the GP workforce in England. This includes measures to boost recruitment, address the reasons why doctors leave the profession, and encourage them to return to practice. NHS England has made available a number of retention schemes, to boost the GP workforce.
Asked by: Helen Grant (Conservative - Maidstone and The Weald)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what progress her Department has made on increasing access to dentists in Maidstone and the Weald constituency.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
In the 24 months to June 2023, 496,306 adults were seen by a National Health Service dentist in Kent and Medway Integrated Care Board (ICB). This figure is 12% higher than the year before, where 444,190 adults were seen by an NHS dentist, in the 24 months to June 2022.
On 7 February 2024, we published Faster, simpler, and fairer: our plan to recover and reform NHS dentistry, which is backed by £200 million and will fund approximately 2.5 million additional appointments. The plan sets out our actions to improve dental access for patients across the country to address the challenges facing NHS dentistry, including in Maidstone and the Weald.
A new patient premium is supporting dentists in taking on new patients, and a new marketing campaign will help everyone who needs an NHS dentist in finding one. We have further supported dentists by raising the minimum Units of Dental Activity rate to £28 this year, making NHS work more attractive and sustainable.
From 1 April 2023, the responsibility for commissioning primary care dentistry to meet the needs of the local population has been delegated to all ICBs across England. Kent and Medway ICB is responsible for having local processes in place to identify areas of need, and determine the priorities for investment across the ICB area.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of vaping on the health of pregnant women; and whether she plans to take steps to encourage pregnant women to stop vaping.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Our health advice on vaping is clear, if you smoke, it is better to vape, but if you don’t smoke, you should never vape. Evidence to date suggests vaping is less harmful than smoking. Research funded by the National Institute for Health and Care Research finds that pregnant women who vaped, when compared to women who used Nicotine Replacement Therapy, were twice as likely to quit, and that both approaches were safer than smoking. Further information is available at the following link:
https://www.nature.com/articles/s41591-022-01808-0
To help pregnant smokers quit smoking, the Government is providing up to £10 million of investment over 2023/24 and 2024/25 via a financial incentives scheme. This evidence-based intervention, supported by behavioural support, will encourage pregnant women to quit smoking, and remain smokefree throughout pregnancy and beyond, helping to improve the health and wellbeing of both mother and baby.
Asked by: Navendu Mishra (Labour - Stockport)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to provide mental health support for the dental workforce.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
The NHS Long Term Workforce Plan commits the National Health Service to supporting staff health and wellbeing, and asks integrated care systems to develop plans to support NHS staff in maintaining their mental health.
The NHS dental workforce is also able to access the NHS Practitioner Health Service. NHS England is in the process of reviewing the service as part of a wider review into its mental health and wellbeing offer to all staff, including the dental workforce.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she has made a recent assessment of the potential merits of creating a national naloxone programme.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Naloxone is highly effective in reducing opioid overdose-related deaths, and the Government is working to widen access to, and increase the uptake of, this life saving drug. A prescription only medicine that is available across the United Kingdom, naloxone can be prescribed by a doctor or non-medical prescriber or provided, under a Patient Group Direction. It can also be supplied without prescription by drug services, which include specialist National Health Service and voluntary sector treatment services, as well as community pharmacies providing other substance misuse services across the UK.
Naloxone has been available for anyone to use in an emergency since 2005. There is good awareness of it, supported by earlier guidance by the Department and its agencies in 2015, 2018, 2019, and 2023. Drug treatment services and their suppliers also provide independent awareness-raising materials, targeting people who use opioids.
The Government launched a UK-wide public consultation to seek views on our proposal to amend the Human Medicines Regulations 2012 so that more professionals, services, and family members can give out take-home naloxone supplies. The consultation closed on 6 March 2024, and the responses are currently being analysed. The Government will publish its official response shortly.
The Government is working to increase naloxone carriage, and has provided additional investment in drug treatment services to support this work. In England, local authorities and their partners have been increasing naloxone supply in recent years. There are now three naloxone products available, and supply has been meeting demand. To enable the Government to respond to any future change in demand for naloxone, the Department is working with the Home Office to model scenarios where demand for naloxone may increase, and has conducted a commercial engagement exercise to better understand the naloxone market, and the market’s capacity to respond to changes in demand.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what her planned timetable is for publishing a response to her Department's consultation on Expanding access to naloxone.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Naloxone is highly effective in reducing opioid overdose-related deaths, and the Government is working to widen access to, and increase the uptake of, this life saving drug. A prescription only medicine that is available across the United Kingdom, naloxone can be prescribed by a doctor or non-medical prescriber or provided, under a Patient Group Direction. It can also be supplied without prescription by drug services, which include specialist National Health Service and voluntary sector treatment services, as well as community pharmacies providing other substance misuse services across the UK.
Naloxone has been available for anyone to use in an emergency since 2005. There is good awareness of it, supported by earlier guidance by the Department and its agencies in 2015, 2018, 2019, and 2023. Drug treatment services and their suppliers also provide independent awareness-raising materials, targeting people who use opioids.
The Government launched a UK-wide public consultation to seek views on our proposal to amend the Human Medicines Regulations 2012 so that more professionals, services, and family members can give out take-home naloxone supplies. The consultation closed on 6 March 2024, and the responses are currently being analysed. The Government will publish its official response shortly.
The Government is working to increase naloxone carriage, and has provided additional investment in drug treatment services to support this work. In England, local authorities and their partners have been increasing naloxone supply in recent years. There are now three naloxone products available, and supply has been meeting demand. To enable the Government to respond to any future change in demand for naloxone, the Department is working with the Home Office to model scenarios where demand for naloxone may increase, and has conducted a commercial engagement exercise to better understand the naloxone market, and the market’s capacity to respond to changes in demand.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent assessment she has made of the availability of naloxone across England.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Naloxone is highly effective in reducing opioid overdose-related deaths, and the Government is working to widen access to, and increase the uptake of, this life saving drug. A prescription only medicine that is available across the United Kingdom, naloxone can be prescribed by a doctor or non-medical prescriber or provided, under a Patient Group Direction. It can also be supplied without prescription by drug services, which include specialist National Health Service and voluntary sector treatment services, as well as community pharmacies providing other substance misuse services across the UK.
Naloxone has been available for anyone to use in an emergency since 2005. There is good awareness of it, supported by earlier guidance by the Department and its agencies in 2015, 2018, 2019, and 2023. Drug treatment services and their suppliers also provide independent awareness-raising materials, targeting people who use opioids.
The Government launched a UK-wide public consultation to seek views on our proposal to amend the Human Medicines Regulations 2012 so that more professionals, services, and family members can give out take-home naloxone supplies. The consultation closed on 6 March 2024, and the responses are currently being analysed. The Government will publish its official response shortly.
The Government is working to increase naloxone carriage, and has provided additional investment in drug treatment services to support this work. In England, local authorities and their partners have been increasing naloxone supply in recent years. There are now three naloxone products available, and supply has been meeting demand. To enable the Government to respond to any future change in demand for naloxone, the Department is working with the Home Office to model scenarios where demand for naloxone may increase, and has conducted a commercial engagement exercise to better understand the naloxone market, and the market’s capacity to respond to changes in demand.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she is taking steps to increase awareness of naloxone.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Naloxone is highly effective in reducing opioid overdose-related deaths, and the Government is working to widen access to, and increase the uptake of, this life saving drug. A prescription only medicine that is available across the United Kingdom, naloxone can be prescribed by a doctor or non-medical prescriber or provided, under a Patient Group Direction. It can also be supplied without prescription by drug services, which include specialist National Health Service and voluntary sector treatment services, as well as community pharmacies providing other substance misuse services across the UK.
Naloxone has been available for anyone to use in an emergency since 2005. There is good awareness of it, supported by earlier guidance by the Department and its agencies in 2015, 2018, 2019, and 2023. Drug treatment services and their suppliers also provide independent awareness-raising materials, targeting people who use opioids.
The Government launched a UK-wide public consultation to seek views on our proposal to amend the Human Medicines Regulations 2012 so that more professionals, services, and family members can give out take-home naloxone supplies. The consultation closed on 6 March 2024, and the responses are currently being analysed. The Government will publish its official response shortly.
The Government is working to increase naloxone carriage, and has provided additional investment in drug treatment services to support this work. In England, local authorities and their partners have been increasing naloxone supply in recent years. There are now three naloxone products available, and supply has been meeting demand. To enable the Government to respond to any future change in demand for naloxone, the Department is working with the Home Office to model scenarios where demand for naloxone may increase, and has conducted a commercial engagement exercise to better understand the naloxone market, and the market’s capacity to respond to changes in demand.